USP <1079> - Good Storage and Distribution Practices for Drug Products

What it says

General Chapter <1079> provides guidance on storage and distribution practices for drug products, addressing temperature and environmental control, transportation qualification, monitoring throughout the distribution chain, and risk-based approaches to determining appropriate control measures for different product types and distribution scenarios.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This chapter provides USP guidance conceptually paralleling EU GDP requirements, addressing the post-manufacturing distribution chain's quality assurance expectations within the US regulatory and pharmacopoeial context.
• Transportation qualification, demonstrating that a specific shipping method and packaging configuration reliably maintains required product conditions, is emphasised as a proactive control measure rather than relying solely on reactive temperature monitoring during actual shipments.
• Risk-based determination of appropriate control measures acknowledges that not every product or distribution scenario requires identical control intensity, with genuinely temperature-sensitive biological products warranting more rigorous controls than more stable, less sensitive product types.

What inspectors look for

• Whether transportation qualification studies genuinely support the shipping methods and packaging configurations actually used in routine distribution.
• Whether temperature monitoring throughout distribution is continuous and reviewed, not just spot-checked at origin and destination.
• Whether the level of distribution control applied is genuinely risk-based and appropriate to the specific product's actual sensitivity, rather than uniformly applied regardless of product characteristics.

Related regulations